TechnologyLtd Past Earnings Performance
Past criteria checks 0/6
TechnologyLtd's earnings have been declining at an average annual rate of -30.5%, while the Life Sciences industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 35.4% per year.
Key information
-30.5%
Earnings growth rate
-9.3%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 35.4% |
| Return on equity | -59.2% |
| Net Margin | -170.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15,895 | -27,111 | 19,409 | 0 |
| 30 Sep 23 | 11,183 | -22,164 | 15,637 | 0 |
| 30 Jun 23 | 6,739 | -19,825 | 13,547 | 0 |
| 31 Mar 23 | 3,365 | -10,732 | 5,672 | 0 |
| 31 Dec 22 | 3,897 | -3,341 | 5,101 | 0 |
| 30 Sep 22 | 9,950 | 2,366 | 5,198 | 0 |
| 31 Dec 21 | 8,848 | -2,239 | 5,234 | 0 |
| 30 Sep 21 | 2,865 | -9,582 | 3,909 | 0 |
| 30 Jun 21 | 3,415 | -7,408 | 3,753 | 0 |
| 31 Mar 21 | 3,780 | -7,449 | 3,609 | 0 |
| 31 Dec 20 | 5,207 | -6,730 | 3,625 | 0 |
| 30 Sep 20 | 5,754 | -6,445 | 4,906 | 4 |
| 30 Jun 20 | 6,017 | -8,530 | 4,874 | 4 |
| 31 Mar 20 | 7,082 | -7,302 | 4,951 | 34 |
| 31 Dec 19 | 7,378 | -8,210 | 5,359 | 152 |
| 31 Dec 14 | 20,672 | -1,616 | 5,398 | 357 |
| 30 Sep 14 | 20,759 | 223 | 3,427 | 335 |
| 30 Jun 14 | 20,298 | 91 | 3,357 | 348 |
| 31 Mar 14 | 20,698 | 508 | 3,044 | 349 |
| 31 Dec 13 | 21,433 | 165 | 2,724 | 381 |
| 30 Sep 13 | 22,851 | -3,045 | 4,765 | 428 |
| 30 Jun 13 | 23,990 | -2,757 | 4,583 | 419 |
Quality Earnings: A043090 is currently unprofitable.
Growing Profit Margin: A043090 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A043090 is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.
Accelerating Growth: Unable to compare A043090's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A043090 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.5%).
Return on Equity
High ROE: A043090 has a negative Return on Equity (-59.2%), as it is currently unprofitable.